2326 related articles for article (PubMed ID: 22078152)
1. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
2. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
[TBL] [Abstract][Full Text] [Related]
3. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
5. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus.
Santilli F; Formoso G; Sbraccia P; Averna M; Miccoli R; Di Fulvio P; Ganci A; Pulizzi N; Lattanzio S; Ciabattoni G; Consoli A; Lauro R; Patrono C; Davì G
J Thromb Haemost; 2010 Apr; 8(4):828-37. PubMed ID: 20088941
[TBL] [Abstract][Full Text] [Related]
6. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
Su JB; Wang XQ; Chen JF; Wu G; Jin Y
Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
[TBL] [Abstract][Full Text] [Related]
7. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
[TBL] [Abstract][Full Text] [Related]
8. Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes.
Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
Diabetes Res Clin Pract; 2016 Mar; 113():108-15. PubMed ID: 26810269
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
10. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
12. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
Fofonka A; Ribeiro JP; Casali KR; Schaan BD
Trials; 2014 Nov; 15():424. PubMed ID: 25366037
[TBL] [Abstract][Full Text] [Related]
13. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
[TBL] [Abstract][Full Text] [Related]
14. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
[TBL] [Abstract][Full Text] [Related]
16. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
17. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
[TBL] [Abstract][Full Text] [Related]
18. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
[TBL] [Abstract][Full Text] [Related]
19. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
